VSV-GP-based cancer vaccine VSV-GP154

A boosting cancer vaccine comprised of the recombinant chimeric oncolytic vesicular stomatitis virus (VSV) viral vector VSV-GP containing as of yet undisclosed peptide(s) derived from as of yet undisclosed tumor-associated antigen(s) (TAAs) that are specific for pancreatic adenocarcinoma patients, with potential immunomodulating and antineoplastic activities. Upon administration, VSV-GP-based cancer vaccine VSV-GP154 preferentially replicates in pancreatic adenocarcinoma cells with KRAS G12D or KRAS G12V mutations. Due to defective antiviral host defense mechanisms in tumor cells, VSV-GP is able to replicate in tumor cells without interference. This induces VSV-mediated cytolytic activity towards the tumor cells. VSV, a single-stranded RNA virus belonging to the genus Vesiculovirus of the family Rhabdoviridae, is relatively nonpathogenic to healthy humans but is able to rapidly replicate in and induce apoptosis of tumor cells. VSV-GP carries the envelope glycoprotein (GP) of the WE-HPI strain of the lymphocytic choriomeningitis virus (LCMV) instead of the native VSV glycoprotein (G). VSV-GP does not induce neutralizing antibodies to the vector itself, which may allow repeated administration. VSV-GP is also not neurotoxic, while wild-type viruses are associated with neural inflammation.